Gary S. Jacob

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
New York, NY
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Gary Jacob
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Gary S. Jacob

Form 4 holding Former Director

Cardiff Oncology, Inc.

Security class
Stock Options
Shares / value
76,106
Estimated value
$197,876
Report date
10 Jun 2021
Price
$2.60
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding CHIEF DEVELOPMENT OFFICER, Director

OKYO Pharma Ltd

Security class
COMMON STOCK
Shares / value
112,420
Estimated value
$180,996
Report date
21 Jul 2026
Price
$1.61
Ownership
Direct
Form 4 holding Director

Hepion Pharmaceuticals, Inc.

Security class
Stock Options
Shares / value
102,120
Estimated value
Report date
19 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Virpax Pharmaceuticals, Inc.

Security class
Stock Option (right to buy)
Shares / value
12,091
Estimated value
Report date
01 Jan 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Gary S. Jacob

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .